Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington. more
Time Frame | CATX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -0.28% | 0.49% | -1.93% |
1-Month Return | -4.11% | -3.1% | -3.69% |
3-Month Return | -73.58% | -8.59% | 0.82% |
6-Month Return | -70.19% | -4.57% | 3.51% |
1-Year Return | -41.67% | -0.94% | 21.91% |
3-Year Return | -5.41% | 2.88% | 24.73% |
5-Year Return | -51.39% | 35.84% | 78.4% |
10-Year Return | -76.97% | 98.8% | 187.28% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 9.68M | 10.05M | 10.79M | 7.10M | 1.43M | [{"date":"2019-12-31","value":89.67,"profit":true},{"date":"2020-12-31","value":93.13,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.81,"profit":true},{"date":"2023-12-31","value":13.28,"profit":true}] |
Cost of Revenue | 4.56M | 4.93M | 6.18M | 5.47M | - | [{"date":"2019-12-31","value":73.73,"profit":true},{"date":"2020-12-31","value":79.82,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":88.53,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | 5.12M | 5.12M | 4.62M | 1.63M | 1.43M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.94,"profit":true},{"date":"2021-12-31","value":90.09,"profit":true},{"date":"2022-12-31","value":31.89,"profit":true},{"date":"2023-12-31","value":27.99,"profit":true}] |
Gross Margin | 52.93% | 50.94% | 42.76% | 23.00% | 100.00% | [{"date":"2019-12-31","value":52.93,"profit":true},{"date":"2020-12-31","value":50.94,"profit":true},{"date":"2021-12-31","value":42.76,"profit":true},{"date":"2022-12-31","value":23,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 8.60M | 8.56M | 18.19M | 17.43M | 42.38M | [{"date":"2019-12-31","value":20.29,"profit":true},{"date":"2020-12-31","value":20.2,"profit":true},{"date":"2021-12-31","value":42.92,"profit":true},{"date":"2022-12-31","value":41.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (3.48M) | (3.44M) | (7.39M) | (15.18M) | (40.94M) | [{"date":"2019-12-31","value":-347600000,"profit":false},{"date":"2020-12-31","value":-343700000,"profit":false},{"date":"2021-12-31","value":-739100000,"profit":false},{"date":"2022-12-31","value":-1518200000,"profit":false},{"date":"2023-12-31","value":-4094100000,"profit":false}] |
Total Non-Operating Income/Expense | 60.00K | 109.00K | - | - | 1.69M | [{"date":"2019-12-31","value":3.56,"profit":true},{"date":"2020-12-31","value":6.47,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (3.45M) | (3.39M) | (7.27M) | (14.67M) | (40.11M) | [{"date":"2019-12-31","value":-344600000,"profit":false},{"date":"2020-12-31","value":-338700000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":-1467000000,"profit":false},{"date":"2023-12-31","value":-4010600000,"profit":false}] |
Income Taxes | (177.00K) | (199.00K) | - | (119.00K) | (2.65M) | [{"date":"2019-12-31","value":-17700000,"profit":false},{"date":"2020-12-31","value":-19900000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-11900000,"profit":false},{"date":"2023-12-31","value":-265100000,"profit":false}] |
Income After Taxes | (3.27M) | (3.19M) | - | - | (37.45M) | [{"date":"2019-12-31","value":-326900000,"profit":false},{"date":"2020-12-31","value":-318800000,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3745500000,"profit":false}] |
Income From Continuous Operations | (3.45M) | (3.39M) | (7.27M) | - | (37.45M) | [{"date":"2019-12-31","value":-344600000,"profit":false},{"date":"2020-12-31","value":-338700000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-3745500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.27M) | (3.19M) | (7.27M) | (14.67M) | (46.51M) | [{"date":"2019-12-31","value":-326900000,"profit":false},{"date":"2020-12-31","value":-318800000,"profit":false},{"date":"2021-12-31","value":-727200000,"profit":false},{"date":"2022-12-31","value":-1467000000,"profit":false},{"date":"2023-12-31","value":-4650800000,"profit":false}] |
EPS (Diluted) | (0.06) | (0.05) | (0.05) | (0.07) | (0.18) | [{"date":"2019-12-31","value":-6,"profit":false},{"date":"2020-12-31","value":-5,"profit":false},{"date":"2021-12-31","value":-5,"profit":false},{"date":"2022-12-31","value":-7,"profit":false},{"date":"2023-12-31","value":-18,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CATX | |
---|---|
Cash Ratio | 9.52 |
Current Ratio | 9.60 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CATX | |
---|---|
ROA (LTM) | -14.35% |
ROE (LTM) | -27.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CATX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CATX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 151.93 |
P/B | 0.72 |
Price/FCF | NM |
EV/R | 68.73 |
EV/Ebitda | NM |
Perspective Therapeutics Inc. (CATX) share price today is $3.436
Yes, Indians can buy shares of Perspective Therapeutics Inc. (CATX) on Vested. To buy Perspective Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CATX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Perspective Therapeutics Inc. (CATX) via the Vested app. You can start investing in Perspective Therapeutics Inc. (CATX) with a minimum investment of $1.
You can invest in shares of Perspective Therapeutics Inc. (CATX) via Vested in three simple steps:
The 52-week high price of Perspective Therapeutics Inc. (CATX) is $19.1. The 52-week low price of Perspective Therapeutics Inc. (CATX) is $2.7.
The price-to-earnings (P/E) ratio of Perspective Therapeutics Inc. (CATX) is
The price-to-book (P/B) ratio of Perspective Therapeutics Inc. (CATX) is 0.72
The dividend yield of Perspective Therapeutics Inc. (CATX) is 0.00%
The market capitalization of Perspective Therapeutics Inc. (CATX) is $233.85M
The stock symbol (or ticker) of Perspective Therapeutics Inc. is CATX